Background: The mechanism by which niacin increases plasma levels of high-density lipoprotein cholesterol (HDL-C) is not clearly understood yet. Adipocytes contain the largest pool of free cholesterol in the body and might play a significant role in cholesterol metabolism. Despite preferential accumulation in adipose tissue, it is not clear whether the actions of niacin on cholesterol efflux from adipocytes contribute to its HDL-raising effect. Methods: Fully differentiated 3T3-L1 adipocytes were incubated in the medium containing various concentrations of niacin (0–1.0 mmol/l) for 24 h. Reverse transcription polymerase chain reaction was used to evaluate peroxisome proliferator-activated receptor-γ (PPARγ), LXRα and ABCA1 mRNA expression in adipocytes. Cholesterol efflux rate was determined by measuring the release of radioactivity from 3H-cholesterolprelabeled cells into medium containing apolipoprotein A-I (ApoA-I). Results: Niacin dose-dependently stimulated PPARγ, LXRα and ABCA1 mRNA expression and promoted ApoA-I-induced cholesterol efflux in adipocytes. Treatment of PPARγ-selective antagonist GW9662 significantly abolished the niacin-induced increase in LXRα and ABCA1 mRNA expression and cholesterol efflux to ApoA-I. Conclusions: Niacin may promote cholesterol efflux from adipocytes to ApoA-I via activation of the PPARγ-LXRα-ABCA1 pathway. To some extent, this effect might help to explain the possible mechanism by which niacin increases plasma HDL-C levels.

Keywords:
Niacin, Adipocytes, Cholesterol efflux, ABCA1, High-density lipoprotein
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.